FDA accepts Sandoz application for biosimilar filgrastim - Seite 3

In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefitted from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).


Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.

###

For further information, contact:

Eric Althoff Novartis Global Media Relations [phone] [phone] [e-mail]	Sreejit Mohan Sandoz Head Biopharma & OI Communications [phone] [e-mail]
Sandoz US Communications Leslie Pott [phone] [phone] [e-mail]

Novartis Investor Relations

Central phone:	[phone]
Samir Shah	[phone]	North America:
Pierre-Michel Bringer	[phone]	Stephen Rubino	[phone]
Thomas Hungerbuehler	[phone]	Susan Donofrio	[phone]
Isabella Zinck	[phone]
e-mail: [e-mail]

Neupogen® is a registered trademark of Amgen Inc.

Media release (PDF)

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire

HUG#1835571

--- End of Message ---

Novartis International AG
P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;